No products in the cart.
Avanafil is a selective inhibitor of phosphodiesterase type 5 (PDE5). It moderates the cyclic guanosine monophosphate (cGMP) as it breaks down and relaxes blood vessel muscles to enhance blood flow to certain areas of the body and is widely used as an erectile dysfunction treatment. Avanafil is a comparably new PDE5 inhibitor that was approved for use in the US by the FDA in 2012 and by EMA in 2013.
Developed by Vivus Inc., avanafil is also known by the trademark names Spedra and Stendra. It performs by inhibiting PDE5 mainly in the corpus cavernosim penis, which allows the majority of users to conduct sexual activity within 15 minutes of consumption. This is considered to be quite fast in comparison to other PDE5 inhibitors on the market. Maximum concentration is reached in around 30-45 minutes.
The recommended dosage of Avanafil is 100 mg for a single dose on an as needed basis, taken one half hour prior to sexual activity. Avanafil is ready for consumption in tablets of 50, 100 and 200 mg. Based on the effects on the user and their tolerance level, dosage can be adjusted, with a maximum recommendation of 200 mg. If users believe they have overdosed on avanafil, emergency medical attention should be sought or the Poison Control Center should be called.